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Abstract
Background: Some patients administered cholesterol-lowering therapies may experience an increase in the
proportion of small LDL particles, which may be misinterpreted as a worsening of atherosclerotic coronary heart
disease risk. This study assessed the lipid effects of adding ezetimibe to atorvastatin or doubling the atorvastatin
dose on low-density lipoprotein cholesterol (LDL-C) levels (and the cholesterol content of LDL subclasses), LDL
particle number (approximated by apolipoprotein B), and LDL particle size. This was a multicenter, double-blind,
randomized, parallel-group study of hypercholesterolemic, high atherosclerotic coronary heart disease risk patients.
After stabilization of atorvastatin 40 mg, 579 patients with LDL-C >70 mg/dL were randomized to 6 weeks of
ezetimibe + atorvastatin 40 mg or atorvastatin 80 mg. Efficacy parameters included changes from baseline in
LDL-C, apolipoprotein B, non-high-density lipoprotein cholesterol (non-HDL-C), and lipoprotein subclasses (Vertical
Auto Profile II) and pattern for the overall population, as well as patient subgroups with baseline triglyceride levels
<150 mg/dL or ≥150 mg/dL.
Results: Both treatments significantly reduced LDL-C (and the cholesterol content of most LDL subfractions
[LDL1-4]) apolipoprotein B, non-HDL-C levels, but did not reduce the proportion of smaller, more dense LDL
particles; in fact, the proportion of Pattern B was numerically increased. Results were generally similar in patients
with triglyceride levels <150 or ≥150 mg/dL.
Conclusions: When assessing the effects of escalating cholesterol-lowering therapy, effects upon Pattern B alone
to assess coronary heart disease risk may be misleading when interpreted without considerations of other lipid
effects, such as reductions in LDL-C, atherogenic lipoprotein particle concentration, and non-HDL-C levels.
Trial Registration: (Registered at clinicaltrials.gov: Clinical trial # NCT00276484)
Introduction
Landmark CHD outcomes trials demonstrate that, in
general, LDL-C lowering therapies reduce CHD risk.
Statin-treated patients who achieve greater LDL-C low-
ering (either through an increase in the same statin dose
or through use of a different statin) have reduced CHD
events compared with statin-treated patients with less
LDL-C lowering [1-3]. In addition, non-high-density
lipoprotein cholesterol (non-HDL-C) and apolipoprotein
B (apo B) may be better predictors of CHD risk than
LDL-C levels [4]. Non-HDL-C is a measure of the cho-
lesterol carried by all atherogenic lipoproteins, such as
the cholesterol carried by LDL particles, as well as the
cholesterol carried by very low-density lipoproteins,
intermediate-density lipoproteins, remnant lipoproteins,
chylomicrons (and their remnants), and lipoprotein (a).
Regarding particle number, one apo B molecule is found
on each lipoprotein particle; thus, apo B level is often
considered a surrogate marker for atherogenic lipopro-
tein particle concentration. An increase in atherogenic
lipoprotein particle number is thought to increase CHD
risk [5,6].
Lipoprotein particle size is another lipid parameter
that may influence CHD risk. A disproportionate
increase in smaller LDL particles is often described as
increasing CHD risk [7]. However, it is unclear whether
LDL particle size provides additional predictive power
for measuring CHD risk versus LDL particle number
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any medium, provided the original work is properly cited.[8]. Various commercial analyses are available for addi-
tional lipid testing, sometimes described as “advanced”
lipid testing. One example is vertical auto profile (VAP),
which is a direct ultracentrifugation method that uses
vertical rotor and single density gradient spin [9].
According to VAP II analyses (Atherotech, Inc.,
Birmingham, AL, USA), low-density lipoprotein particles
are reported as four subclasses based on density. The
larger, more buoyant LDL particles are LDL1 and LDL2,
and the smaller, denser particles are LDL3 and LDL4.
VAP analyses also report the cholesterol carried by each
lipoprotein subclass. An increase in the proportion of
smaller, more dense LDL particles is referred to as Pat-
tern B, which is considered to impart greater CHD risk
[10-14]. HDL-C is a highly heterogeneous lipoprotein
that can be separated into two major subclasses (HDL-
C2 and HDL-C3) and several minor subclasses based on
density. Both major subclasses are inversely related to
CHD risk, [11,15] and low HDL-C and low HDL parti-
cle concentration are associated with increased risk for
CHD [16].
Mechanistically, the proposed increased atherogenicity
of the smaller, more dense LDL particles may be related
to their decreased affinit yf o rt i s s u ea n dl i v e rL D L
receptors, which leads to prolonged LDL particle pre-
sence in the blood, and thus increased exposure to ater-
ioles [17]. In addition, the small, more dense LDL
particles may have increased permeability through the
arterial endothelium and may be preferentially retained
in the arterial wall [18]. Moreover, these particles may
be more readily oxidized, further increasing their athero-
genic potential [19].
A practical, clinical challenge regarding advanced lipid
testing is that the use of lipoprotein pattern analysis for
pre-treatment diagnostic purposes may have very differ-
ent clinical implications than the use of lipoprotein
pattern analysis to assess the efficacy of cholesterol-
lowering therapy. Some clinicians believe that the pre-
sence of pre-treatment Pattern B confers an increased
CHD risk, thus prompting them to be more aggressive
with lipid-altering therapy. But anecdotally, some clini-
cians also believe that a post-treatment shift to Pattern
B likewise increases CHD risk, which may prompt
them to consider discontinuing or altering cholesterol-
lowering therapy. This is of clinical importance given
the wealth of data supporting LDL-C lowering as redu-
cing CHD events [20] and the lack of CHD outcome
data supporting the “improvement” in lipoprotein parti-
cle size as reducing CHD events.
This study analyzed the effects of ezetimibe added to
atorvastatin 40 mg or doubling the atorvastatin dose in
atorvastatin-treated, hypercholesterolemic, high CHD
risk patients [21]. Efficacy parameters included LDL-C
levels, the cholesterol content of LDL and HDL
subclasses, apo B, non-HDL-C levels and LDL particle
size (Pattern). In addition, the same endpoints were
assessed in a post hoc analysis of subgroups of patients
with baseline triglyceride levels <150 mg/dL (normal) or
≥150 mg/dL (elevated), since these levels approximate
the triglyceride threshold by which LDL particle size is
most likely to shift to larger or smaller LDL particles [22].
Methods
T h em e t h o d so ft h i ss t u d yw e r ep r e v i o u s l yp u b l i s h e d
[21]. Briefly, this was a multicenter, double-blind, rando-
mized, parallel-group study conducted at 96 sites in the
US (91) and Canada (5), from April 2006 to February
2008, conducted under Good Clinical Practices guide-
lines. The study protocol underwent review and
approval by institutional review boards and study parti-
cipants provided written informed consent prior to
study procedures being performed. Entry criteria
included hypercholesterolemic adults <80 years who had
CHD, a CHD risk equivalent medical condition, or 2 or
more CHD risk factors and a Framingham Risk Score
estimating a 10-year risk for CHD >20% [23].
Other entry criteria included triglyceride levels ≤350
mg/dL, hemoglobin A1c <8.5%, liver transaminases (ala-
nine aminotransferase [ALT] and aspartate aminotrans-
ferase [AST]) ≤1.5 X the upper limit of normal (ULN)
with no active liver disease, and creatinine kinase (CK)
levels ≤2 X ULN. Patients must have received a stable
daily dose of a statin of equal or lesser LDL-C lowering
efficacy than atorvastatin 40 mg/d, or must have been
naïve to statin, ezetimibe, or ezetimibe/simvastatin ther-
apy. Exclusion criteria included patients taking other
prescription and/or over-the-counter-drugs/supplements
with the potential for significant lipid-altering effects or
therapies with the potential for drug interactions with
atorvastatin.
Treatments
Patients entering the study agreed to follow the National
Cholesterol Education Program therapeutic lifestyle
changes/American Diabetes Association or similar cho-
lesterol-lowering diet throughout the trial. Patients
already taking atorvastatin 40 mg/d at study entry con-
tinued this therapy for a 4-week run-in period. Those
taking a statin with equal or lower LDL-C lowering effi-
cacy and those naïve to lipid-altering drug therapy
received atorvastatin 40 mg/d for a 5-week run-in per-
iod. Following the run-in period, patients were rando-
mized to 6 weeks of atorvastatin 40 mg/d plus ezetimibe
(10 mg) or atorvastatin 80 mg/d.
Efficacy endpoints
In addition to efficacy endpoints in the overall popula-
tion, which included all randomized patients who took
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value and at least one post baseline value, this analysis
also evaluated treatment efficacy at week 6 by subgroups
based on normal and elevated baseline triglycerides
(<150 mg/dL or ≥150 mg/dL). A central laboratory
(PPD, Highland Heights, KY, USA) was utilized, which
measured common lipid parameters, including apo B
and safety laboratory values. For patients with triglycer-
ides ≤400 mg/dL, LDL-C measurements were calculated
by the Friedewald equation. For patients whose trigly-
cerides may have increased to >400 mg/dL during the
study, LDL-C measurement was obtained directly using
beta quantification. VAP II was the method used to
measure lipoprotein particle size, cholesterol content of
the LDL-C1-4 lipoprotein subclasses, and lipoprotein
pattern [9,24].
The VAP II method defines the LDL pattern based on
the value of the LDL max time. Lower LDL max times
(≤115 seconds) correspond to predominantly small and
dense LDL (Pattern B), and higher LDL max times
(≥118 seconds) correspond to predominantly large and
buoyant LDL particles (Pattern A). Patients with LDL
max times between 115 and 118 seconds are identified
as having intermediate pattern (Pattern A/B or Pattern
I) [9].
Statistics
The statistical analyses for the traditional lipid para-
meters were previously described [21]. Treatment group
comparisons of interest were the same as the primary
study comparison (atorvastatin 40 mg + ezetimibe or
atorvastatin 80 mg). Subgroup analysis of patients with
normal (<150 mg/dL) and elevated (≥150 mg/dL) base-
line triglyceride levels utilized nonparametric methods
for median percent change from baseline for LDL sub-
classes 1-4. Determination of mean percent change from
baseline in total LDL-C, apo B, and non-HDL-C utilized
an analysis of covariance model with terms for treat-
ment, baseline variable, triglyceride subgroup, and treat-
ment by triglyceride subgroup interaction. Additionally,
the categorical distribution of R-LDL pattern (A, I, or B)
at baseline and study end was summarized in the overall
population and for both the normal and elevated base-
line triglyceride groups using the Cochran-Mantel-
Haenszel Chi-square statistic. For all of the analyses per-
formed on the subgroups of patients with normal (<150
mg/dL) and elevated (≥150 mg/dL) baseline triglyceride
levels, no inferential statistics were conducted to avoid
issues of multiplicity, although 95% confidence intervals
were calculated.
To provide perspective on interpreting results for
multiple exploratory endpoints and to minimize the
likelihood of falsely identifying a significant treatment
difference, the false discovery rate (FDR) procedure
[25] was applied to the prespecified lipoprotein sub-
class analyses for the overall population. The FDR pro-
cedure was applied at the 0.05 level and included 8
parameters for the LDL family of lipoproteins: LDL
(Total), LDL (Real), R-LDL subclass pattern, LDL-R
peak max time, LDL1,L D L 2,L D L 3,L D L 4;a n d1 0p a r a -
meters for the HDL family of lipoproteins: HDL-C,
HDL2,H D L 2a HDL2b,H D L 2c,H D L 3,H D L 3a,H D L 3b,
HDL3c and HDL3d.
Results
Patients
Enrollment and patient flow through the study was pre-
viously summarized [21]. Of the 579 patients rando-
mized, the majority were white (81%) and male (60.6%).
The mean age was 61 (±10) years.
Among the overall population, baseline Pattern I and
Pattern B were more prevalent than Pattern A (Figure 1).
Pattern B was even more disproportionally higher than
Pattern A in those with triglyceride levels ≥150 mg/dl
(Figure 1).
Total baseline (i.e. while on atorvastatin 40 mg per
day) LDL-C levels were 88.6 and 89.7 mg/dL in the
overall population and 88.3 and 85.6 mg/dL in patients
with normal baseline triglycerides (Table 1). In patients
with elevated triglyceride levels, baseline LDL-C levels
were 88.9 and 96.1 mg/dL (Table 1). Among the overall
population, the individual LDL subclass with the great-
est baseline cholesterol content was the small, denser
LDL3 subclass (Table 1). The cholesterol content in the
LDL3 subclass was greatest in those with elevated trigly-
ceride levels (Table 1). Among the overall population,
baseline apo B was approximately 100 mg/dL, and high-
est among those with elevated baseline triglyceride levels
(Table 1). Finally, baseline non-HDL-C levels were
approximately 118 mg/dL in the overall population, 108
mg/dL in patients with normal baseline triglycerides,
and highest in patients with elevated baseline triglycer-
ides (ranging from 130.9 to 135.5 mg/dL; Table 1).
Lipid effects
LDL-C subclass pattern
Among the overall population, neither atorvastatin 40
mg + ezetimibe nor atorvastatin 80 mg increased Pat-
tern A. In fact, both regimens numerically decreased the
proportion of patients with Pattern A and Pattern I and
increased the proportion of patients with Pattern B
compared with baseline (Figure 1). Athough this pattern
shift did not differ significantly, and although the preva-
lence of both baseline and end-of-study Pattern B was
higher among those with elevated baseline triglyceride
levels, Figure 1 supports a consistency in the direction
of this shift in the overall population, as well as in both
triglyceride subgroups (Figure 1).
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Page 3 of 10Table 1 Baseline and study end median values of Apolipoprotein B and cholesterol content in lipoprotein subclasses
in the overall population and triglyceride subgroups in high risk patients
(mg/dL) Overall Population Baseline Triglycerides
<150 mg/dL
Baseline Triglycerides
≥150 mg/dL
Baseline concentration A40 + EZ n = 225 A80 n = 222 A40 + EZ n = 136 A80 n = 140 A40 + EZ n = 89 A80 n = 82
Triglyceride 131.0 135.5 109.0 107.5 195.8 191.0
Apo B* 101.1 102.0 94.8 94.8 111.7 113.7
Total LDL-C* 88.6 89.7 88.3 85.8 88.9 96.1
LDL1-C 14.0 14.0 14.0 13.0 15.0 16.0
LDL2-C 17.0 16.5 21.0 18.5 10.0 13.5
LDL3-C 38.0 41.5 36.0 39.0 42.0 44.0
LDL4-C 9.0 9.0 7.0 8.0 14.0 13.0
Non-HDL-C* 117.4 118.0 109.3 107.3 130.9 135.5
HDL2-C 9.0 10.0 10.0 10.00 8.0 8.5
HDL3-C 36.0 36.0 38.0 36.0 33.0 34.0
Study end concentration
Triglyceride 117.0 124.0 92.0 104.0 166.5 170.0
Apo B* 82.5 93.2 79.3 87.9 87.7 101.8
Total LDL-C* 64.1 79.1 65.3 76.8 62.2 82.8
LDL1-C 10.0 12.0 9.0 12.0 11.0 13.5
LDL2-C 13.0 15.0 15.0 17.0 10.0 13.0
LDL3-C 29.0 37.0 27.0 35.0 30.0 40.0
LDL4-C 8.0 9.0 7.0 8.0 10.0 11.0
Non-HDL-C* 89.5 106.4 84.8 99.0 97.5 118.6
HDL2-C 10.0 9.5 10.0 10.0 9.0 8.0
HDL3-C 35.0 35.0 37.0 36.0 33.0 34.0
*expressed as mean value; n = 277 for A40 + EZ and n = 279 for A80
A = Atorvastatin; C = cholesterol; EZ = ezetimibe 10 mg; HDL = high-density lipoprotein; LDL = low-density lipoprotein
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Figure 1 Change in LDL subclass pattern in the overall population and by baseline triglyceride levels (<150 or ≥150 mg/dL) in high
risk patients treated for 6 weeks with ezetimibe added to atorvastatin 40 mg vs atorvastatin 80 mg. P-values are for between-treatment
comparison (Atorva 40 + EZ vs Atorva 80)
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Both treatments reduced total LDL-C from baseline
(Table 1), with a significantly greater reduction observed
in the atorvastatin 40 mg + ezetimibe 10-mg group
compared with the atorvastatin 80-mg group in the
overall population (-27.4% vs -11.0%, P < 0.001). Those
with normal baseline triglyceride levels generally had a
similar reduction in LDL-C levels compared with those
who had elevated triglyceride levels (Table 1). Among
the overall population atorvastatin 40 mg + ezetimibe
and atorvastatin 80 mg lowered the cholesterol content
of most LDL subfractions. The degree of cholesterol
lowering in individual subfractions was generally similar
with regard to those with normal or elevated triglyceride
levels (Table 1 and Figure 2), with the exception of the
increased reduction in LDL4 for those with elevated
baseline triglyceride levels.
Figure 2A illustrates that among the overall popula-
tion, atorvastatin 40 mg + ezetimibe lowered the choles-
terol content of LDL1 and LDL3 significantly more than
atorvastatin 80 mg. (adjusted P-values ≤ 0.001). Changes
in the cholesterol content of LDL2 and LDL4 subclasses
were similar between treatment groups (adjusted
P-values > 0.05). No inferential statistics were conducted
in triglyceride subgroups; however, among those with
normal baseline triglyceride levels (Figure 2B), atorvasta-
tin 40 mg + ezetimibe appeared to reduce the choles-
terol content of LDL1,L D L 2,a n dL D L 3 subclasses more
versus atorvastatin 80 mg. Among those with elevated
triglyceride levels (Figure 2C), atorvastatin 40 mg + eze-
timibe appeared to reduce the cholesterol content of
LDL1,L D L 3,a n dL D L 4 subclasses more versus atorvas-
tatin 80 mg.
Apo B and non-HDL-C
Among the overall population, both atorvastatin 40 mg
+ ezetimibe and atorvastatin 80 mg lowered apo B levels
(Table 1; Figure 3). Patients treated with atorvastatin 40
mg + ezetimibe had a significantly greater reduction in
apo B levels compared with atorvastatin 80 mg (-17.8%
vs. -7.7%, P < 0.001: Figure 3). Among the triglyceride
subgroups, the mean percentc h a n g ef r o mb a s e l i n ew a s
greater in patients treated with atorvastatin 40 mg +
ezetimibe compared with atorvastatin 80 mg [normal
triglycerides at baseline (-17.2% vs -8.3%) and elevated
triglycerides at baseline (-18.8% vs -6.7%)] (Table 1 and
Figure 3).
Among the overall population, both atorvastatin 40
mg + ezetimibe and atorvastatin 80 mg lowered non-
HDL-C, with a significantly greater reduction in the
group treated with atorvastatin 40 mg + ezetimibe com-
pared with those treated with atorvastatin 80 mg
(-23.3% vs. -9.0%, P < 0.001: Figure 4). The results were
similar among the triglyceride subgroups (Figure 4).
HDL particle size
In the overall population, the median percent changes
from baseline in the HDL2 and HDL3 subclasses after 6
weeks of treatment with atorvastatin 40 mg + ezetimibe
and atorvastatin 80 mg were both 0.0% (robust standard
deviations were 28.0 and 27.1, respectively). Similar to the
overall study results for HDL2 and HDL3, neither treat-
ment resulted in substantive changes from baseline after 6
weeks of treatment in either of the triglyceride subgroups
(Table 1). For both HDL subclasses, the median percent
changes were 0.0% in both treatment groups, regardless of
baseline triglyceride levels, except the high triglyceride
group treated with atorvastatin 80 mg, which experienced
a -2.5% change from baseline in the HDL3 subclass.
Discussion
In this study, both atorvastatin 40 mg + ezetimibe and
atorvastatin 80 mg lowered LDL-C levels (as well as the
cholesterol content of most LDL subfractions as mea-
sured by VAP II methodology), reduced atherogenic
lipoprotein particle concentration (as measured by apo
B ) ,a n dr e d u c e dn o n - H D L - Cl e v e l s .H o w e v e r ,t r e a t m e n t
with atorvastatin 40 mg + ezetimibe and atorvastatin 80
mg also numerically increased the proportion of patients
with LDL subclass Pattern B. Although these changes
were not statistically significant, Figure 1 supports a
remarkably consistent shift in all studied groups from
Pattern A to Patterns I & B, and Pattern I to Pattern B
in the overall study group, as well as study participants
with TG <150 and ≥150 mg/dL.
Despite the numerous published statin studies, prior
reports of the effects of statins on Pattern B are scarce
and inconsistent, possibly because of the questionable
clinical relevance of this parameter as a post-treatment
measure, and the potential misinterpretation of the
results. Regarding atorvastatin, a previous, uncontrolled,
small trial (n = 26) of hypercholesterolemic patients
using nuclear magnetic resonance (NMR) revealed that
atorvastatin 10 mg a day significantly lowered LDL-C
levels, significantly reduced LDL particle number, signif-
icantly reduced the cholesterol content of LDL sub-
classes (large and small), significantly increased overall
LDL particle size, but had no significant effect upon Pat-
tern B [26]. In a larger, placebo-controlled study of 217
dyslipidemic patients with type 2 diabetes mellitus,
using polyacrylamide gradient gel electrophoresis, ator-
vastatin 10 mg and 80 mg significantly lowered LDL-C
levels, significantly reduced apo B, and produced no sig-
nificant effects upon LDL particle size. However, similar
to this report, atorvastatin produced a numerical
increase in the proportion of patients with Pattern B
(21.3%, 21.4%, and 22.2% for placebo, atorvastatin 10
mg, and atorvastatin 80 mg, respectively) [27].
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Figure 2 Median percent change from baseline and between-treatment differences (A40+EZ minus A80) in cholesterol content of
lipoprotein subclasses (LDL-C1-4) after treatment with ezetimibe added to atorvastatin 40 mg vs doubling to atorvastatin 80 mg for 6
weeks in the overall population and in subgroups with baseline triglyceride <150 or ≥150 mg/dL. Numbers below bars in figures B and C
represent the between-treatment difference (95% confidence interval). B. Baseline triglycerides <150 mg/dL. C. Baseline triglycerides ≥150 mg/dL.
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protein particle size may be dependent upon the lipid-
altering drug used in combination with the statin.
Generally, an increase in LDL particle size would be
expected with niacin, [28] omega-3-fatty acids [29] or
fibrates [30]. Similarly, ezetimibe combined with fenofi-
brate reduces LDL-C levels, reduces atherogenic lipopro-
tein particle concentration as measured by a reduction in
apo B and reduces non-HDL-C. The proportion of
patients with Pattern B in those administered ezetimibe
and fenofibrate is reduced as well [31,32]. In prior studies
with ezetimibe monotherapy, or ezetimibe combined
with statins, LDL particle size was either increased, [33]
remained the same, [34] or decreased [35].
In a smaller, single-site study of 72 healthy men
involving simvastatin and ezetimibe, lipoprotein parti-
cle size (determined by gradient gel electrophoresis)
suggested that ezetimibe alone or in combination with
simvastatin increased small, dense LDL particles. The
authors concluded: “In healthy men, treatment with
ezetimibe alone is associated with the development of a
pro-atherogenic LDL subfraction profile. Potentially
atheroprotective effects of simvastatin are offset by eze-
timibe.” [36] However, the authors acknowledged that
statin, ezetimibe, and the combination of ezetimibe
and statin all “decreased the large, more buoyant LDL-I
subfraction.” To the extent that this reflects a decrease
in the number of atherogenic particles, then this would
seem to be a favorable lipid effect. Furthermore, this
single-site study was not a CHD outcomes study. It is
therefore unclear how the authors’ data support their
claim that the atheroprotective effects of statins are
“offset” by ezetimibe, based upon their reported pro-
portional effects on lipoprotein particle size alone, and
irrespective of effects upon LDL-C, non-HDL-C, and
apo B levels and especially given the lack of objective
atherosclerosis data in their small, single-site study.
This is potentially an illustrative example of how
advanced lipid testing results might be misinterpreted
when considered outside the context of other lipid
effects, such as reductions in LDL-C levels and reduc-
tions in particle number (apo B), which (as previously
described) have far more data supporting potential
CHD outcomes benefits, compared to virtually no
CHD outcome data regarding changes in lipoprotein
particle size.
If therapy with a cholesterol-lowering drug can shift
patients to Pattern B, what are the potential mechan-
isms? Impaired LDL clearance is one of the proposed
mechanisms accounting for the potential increased
atherogenicity of smaller, more dense LDL particles
[17]. Studies using LDL particle subspecies from normo-
lipidemic subjects suggest that the small, dense LDL
subspecies have lower receptor binding activity com-
pared with the larger, more buoyant LDL particles [17].
It might therefore be expected that, when hepatic LDL
receptors are unregulated (as occurs with both ezetimibe
and statins) [37], this would preferentially remove the
larger circulating LDL particles, which are most easily
cleared. So while the cholesterol from all LDL subclasses
is reduced, the cholesterol carried by the larger particles
m a yb ep r e f e r e n t i a l l yr e d u c e d ,r e s u l t i n gi nad i s p r o p o r -
tionate number of small, denser particles left uncleared,
and thus resulting in a post-treatment shift to Pattern B.
It is also possible that once LDL-C is rendered below
100 mg/dL, the incorporation of cholesterol into larger
LDL particles is reduced [35,38].
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A40 +EZ: n = 136; A80: n = 140; Baseline triglycerides ≥150 mg/dL,
A40 +EZ: n = 89; A80: n = 82
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Figure 4 Mean % change from baseline in non-HDL-C after
treatment with ezetimibe added to atorvastatin vs doubling
the atorvastatin dose for 6 weeks in the overall population
and in subgroups with baseline triglycerides (BL TG) <150 or
≥150 mg/dL. Numbers below bars represent the between
treatment difference (95% confidence interval). Overall population,
A40 + EZ: n = 225; A80: n = 222; Baseline triglycerides <150 mg/dL,
A40 + EZ: n = 136; A80: n = 140; Baseline triglycerides ≥150 mg/dL,
A40 + EZ: n = 89; A80: n = 82
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Page 7 of 10This analysis is limited by the utilization of only one
methodology to assess lipoprotein particle size and pattern
shift. However, this report is one of only a few to report
lipoprotein particle size with statin therapy, with or with-
out ezetimibe. While the results of the current analysis are
generally consistent with previous reports, this study is at
variance with some other reports regarding the effects of
statin and ezetimibe upon Pattern B. This may be due to
differences in the nature or number of study participants,
differences in lipid entry criteria, differences in the lipid-
altering agents being assessed, the presence or absence of
a control group, and the varied methodologies used to
assess particle size and LDL subclasses. However, it is also
possible that the variance of this report from some other
prior reports is due to publishing bias against prior report-
ing what might be perceived as “negative” data, or because
the effects of statin therapy upon Pattern B is thought to
be of questionable clinical significance. This latter explana-
tion is supported by the relative lack of available literature
regarding the effects of statins upon Pattern B, relative to
t h ev a s ta m o u n to fp u b l i s h e dliterature on the effects of
statins on other lipid parameters. Another potential limita-
tion of this study is that baseline lipid values did not repre-
sent a treatment-naïve population. Therefore, the results
reflect the effects of a change in atorvastatin 40 mg/d (i.e.,
addition of ezetimibe or increase in atorvastatin to 80 mg)
rather than the change from pre-treatment levels. In addi-
tion, due to the post hoc nature of some of the analyses,
no inferential statistics were conducted for change from
baseline in pattern shift or in triglyceride subgroups.
Finally, this study provides no direct insight into the CHD
outcome merits of particle size and pattern analysis,
though other data are available demonstrating the cardio-
vascular benefits of LDL-C, apo B, and non-HDL-C reduc-
tions with statin treatment [39-41].
From a clinical standpoint, although a shift to Pattern
B may be misinterpreted by some clinicians, others who
advocate for “advanced lipid testing” may not interpret a
shift to Pattern B as a detrimental finding with choles-
terol-lowering therapy. Instead, these clinicians may per-
ceive the persistence or emergence of Pattern B as an
indicator to implement additional lipid-altering therapy
that might best reduce the prevalence of Pattern B, such
as therapeutic use of niacin, omega-3 fatty acids, or
fibrates. Having said this, CHD outcomes data do not
yet exist in determining the potential efficacy, or cost
effectiveness, of a lipid management approach based on
effects on particle size and pattern. It is simply unknown
how much residual CHD risk can be alleviated through
solely altering lipoprotein pattern and size.
Conclusion
These results suggest that clinicians should be cautious
when interpreting post-treatment lipoprotein particle
size pattern results. When assessing the efficacy of
cholesterol-lowering therapy, including escalation of
cholesterol-lowering therapy as demonstrated in this
trial, most CHD outcomes evidence suggests that clini-
cians should focus on more established efficacy para-
meters, such as the reduction in the cholesterol carried
by LDL particles, atherogenic lipoprotein particle con-
centration (approximated by apo B), and non-HDL-C
levels.
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